Wani SH, Lone SA (2018) Cancer: diseases. Educreation Publishing

Brown JS et al (2023) Updating Definition Cancer. Mol Cancer Res 21(11):1142–1147

CAS  Google Scholar 

Kotamkar S, Bankar (2021) A brief research on Cancer. J Cancer Immunother 33(38B):323–329

Google Scholar 

Chhikara BS (2023) KJCBL Parang Global cancer statistics 2022: the trends projection analysis. Chem Biol Lett 10(1):451–451

Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 74(3):229–263

Li C, He W-Q (2023) Global prediction of primary liver cancer incidences and mortality in 2040. J Hepatol 78.4:e144–e146

Ng R et al (2020) Smoking, drinking, diet and physical activity—modifiable lifestyle risk factors and their associations with age to first chronic disease. Int J Epidemiol 49(1):113–130

Guzha BT et al (2024) The Impact of DNA Tumor Viruses in low-to-middle income countries (LMICS): a literature review. Tumour Virus Res, p 200289

Xiong X et al (2025) Breast Cancer: Pathogenesis Treatments. Signal Transduc Target Ther 10(1):49

Ying X et al (2024) Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform ‘cold’tumors into ‘hot’tumors. Mol Cancer 23(1):277

Article  PubMed  PubMed Central  Google Scholar 

De Freitas LF, Hamblin MR (2016) Proposed Mech Photobiomodulation or low-level Light Therapy. IEEE J Sel Top Quantum Electron 22(3):348–364

Glass G (2021) Photobiomodulation: rev mol evid low level light therapy. Reconstructive, Surgery A 74(5):1050–1060

Google Scholar 

Shabnum SS et al (2024) Advancements in nanotechnology-driven photodynamic and photothermal therapies: mechanistic insights and synergistic approaches for cancer treatment. RSC Adv 14(52):38952–38995

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ay E, Acar DH (2024) Potential appl photobiomodulation comb cancer therapy: developments diagnosis treat. J.J.o.O F 10(1):47–59

Google Scholar 

Sharma GN et al (2010) Var Types Manage Breast Cancer: Overv 1(2):109

Google Scholar 

Albeshan S et al (2023) Assessment of Knowledge and Awareness About Breast Self-Examination Among University Female Students in Saudi Arabia. Targets Ther, pp 91–99

Zengin HB et al (2024) Eczematous’ dermatitis of the nipple: clinical and histopathological differential diagnosis of Paget disease. Pathology. https://doi.org/10.1016/j.pathol.2023.10.018

Article  PubMed  Google Scholar 

Toyga S, Yıldırım F (2024) A comparative approach to phyllodes tumors in women and phyllodes-like tumors in female dogs. 8(2):214–220

Khalid A et al (2023) Breast Cancer Detect Prev Using Mach Learn 13(19):3113

CAS  Google Scholar 

Ghasemi-Kebria F et al (2024) Breast cancer incidence trends in Golestan, Iran: an age-period-cohort analysis by ethnic region, 2004–2018. Cancer Epidemiol 89:102525

Article  PubMed  Google Scholar 

Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

PubMed  Google Scholar 

Admoun C, Mayrovitz HN (2022) The etiology of breast cancer.

Hibino S et al (2021) Inflammation-induced Tumorigenesis Metastasis. Int J Mol Sci 22(11):5421

Obstetricians ACo, Gynecol GJO (2019) Hereditary Cancer Syndr Risk Assess 134(6):e143–e149

Google Scholar 

Kaur S (2024) Genetic contribution to breast cancer: a critical analysis of penetrance alleles as susceptible genes. D.J.J.o.E.R.i.P. Singh 9(1):60–64

Google Scholar 

Barili V et al (2024) Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition testing. Genes 15(2):219

Article  PubMed  PubMed Central  CAS  Google Scholar 

da Silva DB, Pianovski MAD (2024), and N.P.J.J.d.P. De Carvalho Filho. Environ Pollution Cancer

Satpathi S et al (2023) Unveiling the role of hormonal imbalance in Breast Cancer Development: Compr Rev 15(7)

Hossack M-SA (2024) Clonal hematopoiesis of indeterminate potential as a mediator of radiation toxicities. University of Toronto (Canada)

Huotari E (2024) Discovery of diagnostic biomarkers and targeted therapy for ductal carcinoma in situ (DCIS).

Wang J et al (2024) Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduct Target Ther 9(1):83

Article  PubMed  PubMed Central  CAS  Google Scholar 

Feng Y et al (2018) Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis [Internet]. ; 5 (2): 77–106. 2020

Kumari Y et al (2024) Different Mol Subtypes Invasive Breast Carcinoma. J Soc Obstet Gynaecol Pak 14(3):330–335

Dixon CJ (2022) Identifying genetic differences among African American and Caucasian triple negative breast cancer genotypes. Texas Southern University

Ran R et al (2024) Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study. BMC Cancer 24(1):1216

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yuan N et al (2014) Clinical characteristics and prognostic analysis of triple‑negative breast cancer patients.;. Mol Clin Oncol 2(2):245–251

Article  PubMed  Google Scholar 

Abuhadra N et al (2022) Early-stage triple-negative breast cancer: time to optimize personalized strategies. Oncologist 27(1):30–39

Article  PubMed  PubMed Central  Google Scholar 

Lau KH, Tan AM, Shi Y (2022) New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci 23(4):2288

Riis M (2020) Modern surgical treatment of breast cancer. Ann Med Surgery 56:95–107

Schneeweiss A et al (2022) Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer 160:100–111

Article  PubMed  CAS  Google Scholar 

Sella T et al (2018) Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort. Breast 40:141–146

Article  PubMed  Google Scholar 

Speers C, Pierce LJJJ (2016) Postoperative radiotherapy after breast-conserving surgery for early-stage breast cancer: a review. JAMA Oncol 2(8):1075–1082

Article  PubMed  Google Scholar 

Pegram M, Jackisch C, Johnston SRD (2023) Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. NPJ Breast Cancer 9(1):45

Newton EE et al (2022) Molecular targets of triple-negative breast cancer: where do we stand?. Cancers 14(3):482

Article  PubMed  PubMed Central  CAS  Google Scholar 

Berger ER et al (2021) Immunotherapy Treat Triple Negat Breast Cancer. Pharm 14(8):763

Marra A, Curigliano GJTCJ (2021) Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy. Cancer J 27(1):41–49

Article  PubMed  CAS  Google Scholar 

Obidiro O, Battogtokh G, Akala EOJP (2023) Triple Negat Breast Cancer Treat Options Limitations: Future Outlook 15(7):1796

CAS  Google Scholar 

Audisio A et al (2024) Neoadjuvant chemotherapy for early-stage colon cancer. Cancer Treat Rev 123:102676

Article  PubMed  CAS  Google Scholar 

Masood SJWsH (2016) Neoadjuvant Chemother Breast Cancers 12(5):480–491

Google Scholar 

Sparano JA et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121

Furlanetto J, Loibl SJBC (2020) Optimal systemic treatment for early triple-negative breast cancer. Breast Care 15(3):217–226

Article  PubMed  PubMed Central  Google Scholar 

Abdul-Rahman T et al (2024) The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review. Eur J Med Res 29(1):124

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mattioli R et al (2023) Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. Mol Asp Med 93:p101205

Drooger JC et al (2016) Toxicity of (neo) adjuvant chemotherapy for BRCA1-and BRCA2-associated breast cancer. Breast Cancer Res Treat 156:557–566

Caramelo O et al (2022) Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis. Hered Cancer Clin Pract 20(1):1–18

Article  Google Scholar 

Cardinale D, Iacopo F (2020) M.J.F.i.c.m. Cipolla. Cardiotoxicity Anthracyclines. Front Cardiovasc Med 7:26

Eisen A et al (2015) Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. 22(s1):67–81

Mosca L et al (2021) Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resist Updat 54:p100742

Abuhadra N et al (2022) Prognostic impact of high baseline stromal tumor-infiltrating lymphocytes in the absence of pathologic complete response in early-stage triple-negative breast cancer. Cancers 14(5):1323

Article  PubMed  PubMed Central  CAS  Google Scholar 

Skarlos P et al (2012) Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic cooperative oncology group (HeCOG) randomized phase III trial. Cancer Chemother Pharmacol 69:533–546

Ojima I et al (2016) Taxane Anticancer Agents: Patent Perspective 26(1):1–20

CAS  Google Scholar 

Lyseng-Williamson KA, Fenton CJD (2005) Docetaxel: Rev its Use Metastatic Breast Cancer 65:2513–2531

CAS  Google Scholar 

Nawara HM et al (2021) Paclitaxel-based chemotherapy targeting cancer stem cells from mono-to combination therapy. Biomed 9(5):500

Abdoul-Latif FM et al (2023) An overview of cancer in Djibouti: current status, therapeutic approaches, and promising endeavors in local essential oil treatment. Pharmaceuticals 16(11):1617

Article  PubMed  PubMed Central  CAS